and require renal replacement therapy, the latter being associated with signifi cant mortality, a lower quality of life, and high costs for national health systems. Thus, new treatment strategies that slow down, halt or even revert progressive renal damage are requested. Current treatments for chronic renal failure target to correct renal hemodynamics, proteinuria, high blood pressure, hyperparathyroidism or to avoid nephrotoxic drugs and nicotine abuse. A general role of immunosuppressive drugs in chronic kidney disease is not established, because of lack of effi cacy or unacceptable side effects of systemic immunosuppression.
Introduction
The global burden of chronic kidney diseases remains an ongoing medical challenge. Therapies that can halt or reverse advanced renal injury are not available. Increasing numbers of patients progress to end-stage renal failure tors are designated according to the class of their chemokine ligands, e.g. CR, CCR, CXCR, and CX3CR ( table 1 ). Chemokine receptors show restricted expression on subclasses of leukocytes. Because the ligand specifi cities of the receptors can substantially overlap within a chemokine class, a high degree of redundancy of single chemokines was suspected [5, 8] . In general, the proinfl ammatory chemokine receptors have promiscuous ligand binding specifi cities. This fi nding gave rise to the concept that blocking chemokine receptors could represent a rational approach to target the chemokine system rather than targeting a single chemokine.
Chemokines and Chemokine Receptors Mediate Leukocyte-Endothelial Cell Interactions
Chemokines are involved in the interactions of leukocytes and activated endothelial cells at multiple stages [5, 11] . Injured renal cells produce infl ammatory mediators that enhance the expression of adhesion molecules on endothelial cells of capillaries adjacent to the infl ammatory lesion. Selectins mediate the rolling process of leukocytes along the endothelial surface and thereby allow contact of leukocytes with chemokines. The Duffy antigen receptor for chemokines (DARC) can bind chemokines Ligand  Receptors  Ligand  Receptors   CXCL1  Gro␣  CXCR1, 2  CCL1  I-309  CCR8  CXCL2  Gro␤  CCL2  MCP-1  CCR2  CXCL3  Gro␥  CCL3  MIP-1␣  CCR1, 5  CXCL4  PF4  CXCR1, 2  CCL4  MIP-1␤  CCR5  CXCL5  ENA-78  CXCR2  CCL5  RANTES  CCR1, 3, 5  CXCL6  GCP-2  CXCR1, 2  CCL7  MCP-3  CCR1, 2  CXCL7  NAP-2  CXCR2  CCL8  MCP-2  CCR1, 2, 5  CXCL8  IL-8  CXCR1, 2  CCL11  Eotaxin  CCR3  CXCL9  Mig  CXCR3  CCL13  MCP-4  CCR1, 2, 3  CXCL10  IP-10  CXCR3  CCL14  HCC-1  CCR1  CXCL11  I-TAC  CXCR3  CCL15  HCC-2  CCR1  CXCL12 SDF at post-capillary venules [12] . However, in various forms of renal diseases, DARC expression expands to peritubular vessel endothelium and thereby marks specifi c exit sites for leukocytes into the renal interstitium [12] . Chemokines ligate their respective receptors on the surface of the rolling leukocyte. This activates leukocyte-expressed ␤ 2 -integrins, resulting in fi rm adhesion of the leukocyte to the endothelial surface as a prerequisite for leukocyte transmigration [5, 7, 13] . Other chemokine receptors appear to differentially infl uence spreading, diapedesis, and subsequent migration into the tissue space [5, 14] . For example, monocytes and T cells express both chemokine receptors CCR1 and CCR5 [15] . In an in vitro system it was found that immobilized CCL5 induced leukocyte arrest via CCR1, while leukocyte spreading was mediated via CCR5, and transendothelial migration was supported by both receptors [15] . In this context it is of interest that chemokines also modulate the redistribution of junctional adhesion molecules at endothelial cell tight junctions that may promote leukocyte diapedesis by transient opening of focal cell-cell contacts [16] . Furthermore, CCL5 up-regulates the secretion and activity of matrix metalloproteinases by infi ltrating leukocytes [17] , thus facilitating leukocyte transmigration through the basement membrane and extracellular matrix [18] .
Chemokines and Chemokine Receptors in Renal
Infl ammation All types of renal cells can produce chemokines upon stimulation [ reviewed in 11] . Proinfl ammatory stimuli including reactive oxygen species, growth factors and vasoactive agents like angiotensin II can stimulate chemokine production of renal cells. Furthermore, immune complexes and complement activation cause mesangial production of chemokines. In proximal tubular cells, chemokines can be induced by LPS [19] , high concentrations of albumin [20, 21] or exposure to both calcium oxalate and calcium phosphate crystals [22] . Besides intrinsic renal cells, infi ltrating leukocytes are a major source of local chemokine production in a positive amplifi cation loop [23, 24] , as chemokines secreted by infi ltrating leukocytes promote additional leukocyte recruitment [25] . It is important to note that chemokine expression is restricted to the injured compartment of the kidney [ reviewed in 26] . The spatial expression of chemokines in the kidney correlates with the local accumulation of infl ammatory cell infi ltrates and renal damage [2, 24] . Data from animal models have been confi rmed by human renal biopsy studies [12, [27] [28] [29] .
Termination of the trigger injury correlates with a reduction of chemokine expression by intrinsic renal cells and infi ltrating leukocytes [30] . As further infl ux of leukocytes does not occur, the number of infi ltrating leukocytes declines in parallel to the resolution of disease. It is important to note that termination of the chemokine signal is critical for the resolution of the infl ammatory process. If local chemokine expression is augmented by another trigger of chemokine release, a pre-existing renal disease may eventually progress to severe renal damage. For example, intercurrent infections frequently result in a deterioration of renal diseases including chronic transplant nephropathy. The proinfl ammatory signals of bacterial and viral invasion are mediated by Toll-like receptors (TLRs) [31] . TLRs recognize pathogen-associated molecules such as LPS, peptidoglycanes, and unmethylated CpG-DNA [31] . We recently found that injection of unmethylated CpG-DNA into mice with otherwise selflimiting immune complex glomerulonephritis resulted in progression instead of resolution of the disease process. This was associated with increased chemokine expression and subsequent glomerular macrophage recruitment [32] . Even if the triggering injury subsides, renal chemokine expression can be maintained by other mechanisms such as infection, renin-angiotensin activation, hypoxia or proteinuria, and contribute to persistent leukocyte infi ltration and tissue damage. Many studies addressed the functional role of single chemokines or chemokine receptors in defi ned renal disease models by applying either neutralizing antibodies, DNA vaccination, chemokine receptor antagonists, or by using mutant mice [ reviewed in 24] . Among those, only a few studies have administered specifi c antagonists late in the disease process, which most appropriately mimics treatment of established kidney disease. Such data is only available for specifi c blockade of CCR1.
Identifying CCR1 as a Target
Human CCR1 binds several CC chemokines, including CCL3 ( table 1 ) . The amino acid sequence of human CCR1 has a high degree of homology to murine CCR1 ( fi g. 1 ). However, species-specifi c pharmacodynamics need to be defi ned for each antagonist when to be tested in another species [33] . The latter often compromises the interpretation of data generated in rodents that apply chemokine antagonists designed for the human system. CCR1 is expressed at low levels on T cells. By contrast, human and murine blood monocytes, tissue macrophages, neutrophils, and eosinophils express CCR1 at high levels [3, 29, 34] . Upon ligation with its ligands, a conforma-tional change of the seven-transmembrane elements of CCR1 leads to intracellular activation of G-protein subunits. Studies using an in vitro fl ow chamber system fi rst identifi ed a critical role for CCR1 for adhesion of rolling macrophages or T cells to activated endothelium using established human cell lines [15] . These fi ndings were validated in vivo by two approaches. First, we used intravital microscopy of the cremaster muscle in mice to study the role of CCR1 for leukocyte rolling, fi rm adhesion, transendothelial migration, and interstitial migration. Either by applying a specifi c CCR1 antagonist or performing intravital microcopy in CCR1-defi cient mice, we found that CCR1 is required for leukocyte adhesion and transendothelial migration during the recruitment process [35] . The coherent fi ndings in antagonist-treated mice or CCR1-defi cient mice argue for a non-redundant role of CCR1 in that processes. Because organ-specifi c roles of chemokines and chemokine receptors have been reported, studies performed on cremaster muscles do not allow a conclusion upon the role of CCR1 in the kidney. Thus, as a second approach we isolated macrophages and T cells from spleens of CCR1-defi cient or wild-type mice.
After ex vivo labeling with a fl uorescence dye, cells were injected into mice with renal fi brosis after unilateral ureteral obstruction (UUO) [36] . CCR1-defi cient macrophages and T cells showed markedly reduced recruitment to the interstitial compartment of diseased kidneys as compared to cells isolated from wild-type mice [36] . These data show that CCR1 on macrophages and T cells is required for interstitial leukocyte recruitment in renal fi brosis in mice.
Compartment-Specifi c Role of CCR1
Human renal biopsy studies have localized renal CCR1 expression to macrophages in glomerular and interstitial infl ammatory cell infi ltrates in several types of kidney disease [29] . However, the presence of a receptor found on cells that infi ltrate the kidney does not necessarily provide evidence for its functional role in the recruitment process. In fact, organ-and even compartment-specifi c roles of chemokine receptors may occur. When we treated autoimmune MRL lpr/lpr mice with lupus nephritis with BX471, a small molecule CCR1 antagonist, we noted that despite a marked reduction of interstitial leukocyte counts, the number of glomerular macrophages was not affected compared to vehicle-treated MRL lpr/lpr mice [37] . Cell transfer studies with labeled leukocytes revealed that CCR1, while critical for interstitial leukocyte recruitment, is not required for their recruitment into the glomerular compartment of nephritic MRL lpr/lpr mice. We obtained similar results in BALB/c and BKS mice with glomerular pathology. By contrast, we could show that CCR5 mediates glomerular but not interstitial macrophage recruitment [23, 36] . Given the fact that CCR1 and CCR5 are present on circulating monocytes and T cells, other factors appear to determine their selective roles for recruitment in different microvascular beds. The interaction of chemokines with their receptors requires additional molecules, e.g. respective binding sites on endothelial cell proteoglycans or DARC that expose the chemokine to the luminal endothelial cell membrane. If endothelial cells of glomerular or peritubular capillaries expose different chemokines in mice, and if these observations hold true for the human kidney, remains a future goal of our ongoing research activities in this fi eld.
Late Onset CCR1 Antagonism with a Small Molecule CCR1 Blocker in Models of Progressive Kidney Disease

Acute and Chronic Renal Allograft Rejection
The fi rst study that used the small molecule CCR1 antagonist BX471 in kidney disease was reported by Horuk et al. [38] in 2001. In this study, BX471 monotherapy had benefi cial effects on serum creatinine levels and renal survival in a model of kidney transplantation in rabbits. Pathologic analysis showed that BX471 was similar to cyclosporine in its ability to prevent extensive infarction of transplanted kidneys [38] . Furthermore, BX471 prevented chronic allograft nephropathy in a Fischer 344 into Lewis rat model of acute and chronic allograft rejection [39] . BX471 given from day 21 to 42 after kidney transplantation reduced the number of ED-1-positive macrophages in renal allografts in association with a reduction of markers of renal fi brosis.
Obstructive Nephropathy
Experimental UUO represents a model for obstructive nephropathy but also allows insight into the process of interstitial fi brosis that is a common characteristic of many chronic nephropathies. UUO kidneys show increased CCR1 expression as compared to their respective non-obstructed contralateral kidneys [40] . UUO kidneys from mice treated with the CCR1 antagonist BX471 revealed a marked reduction of interstitial leukocyte counts [41] . Markers of renal fi brosis, such as interstitial fi broblasts, interstitial volume, mRNA and protein expression for collagen I, were all signifi cantly reduced by BX471 compared to vehicle-treated controls. Most interestingly, the benefi cial effect was comparable when BX471 was given not before day 6, indicating that late onset of CCR1 blockade may still be effective. By contrast, treatment was ineffective when the drug was supplied only from day 0 to day 5. These data were confi rmed by inducing UUO in CCR1-defi cient mice [36] . Thus, we decided to further evaluate CCR1 as a potential target for reducing interstitial leukocyte recruitment and fi brosis as major factors for the process of progression to end-stage renal failure.
Immune Complex Glomerulonephritis
Chemokines are also involved in systemic immune responses [3] , so that data from the UUO model may not apply to renal manifestations of systemic autoimmunity, e.g. lupus nephritis. In fact, lack of CCR1 has been reported to be associated with an enhanced Th1-like immune response and aggravation of nephrotoxic serum nephritis [42] . We therefore studied the effects of therapeutic CCR1 blockade in progressive lupus-like immune complex glomerulonephritis of MRL lpr/lpr mice. BX471 treatment initiated late during the course of disease (weeks 20-24 of age) improved blood urea nitrogen levels and reduced the amount of macrophages and lymphocytes in the interstitium [37] . Furthermore, BX471 reduced the extent of interstitial fi brosis as evaluated by interstitial smooth muscle actin expression and collagen I deposits, as well as mRNA expression for collagen I and TGF-␤ 1 . BX471 did not affect serum DNA autoantibodies despite potential roles of CC chemokines and their receptors in systemic immune responses. As CCR1 blockade does not reduce glomerular macrophage recruitment, it was found to be ineffective in modulating glomerular pathology and proteinuria in MRL lpr/lpr mice.
Focal Segmental Glomerulosclerosis
Proteinuria represents a major prognostic factor for the progression of renal disease, because unselective proteinuria can induce chemokine expression in renal tubular cells [43] . Thereby proteinuria serves as a major factor for tubulointerstitial infl ammation. Thus, we questioned whether CCR1 antagonism would be able to improve interstitial fi brosis in the presence of massive proteinuria caused by focal segmental glomerulosclerosis (FSGS).
FSGS was induced in BALB/c mice by two intravenous injections of adriamycin at day 0 and 14. BX471 was started from day 14 when nephrotic syndrome was established. Again, BX471 reduced the amount of interstitial macrophages and T cells and markers of renal fi brosis including interstitial fi broblasts and interstitial volume [44] . These fi ndings demonstrate that therapeutic CCR1 blockade is effective in the presence of heavy proteinuria. Consistent with our previous fi ndings, BX471 did not affect glomerular pathology in adriamycin-injected BALB/c mice.
Glomerulosclerosis in Alport Nephropathy
Alport syndrome is a common type of hereditary glomerulopathy leading to glomerulosclerosis with subsequent interstitial fi brosis progressing to end-stage renal disease. Disease progression has been thought to be mediated mostly by non-infl ammatory factors, but recent studies have documented the role of interstitial macrophages for tubular atrophy in collagen4A3-/-mice, with renal lesions comparable to humans [45] . We treated collagen4A3-/-mice with BX471 or vehicle beginning from 6 weeks of age for 4 weeks [35] . Vehicle-treated collagen4A3-/-mice showed a mean survival of 69 days (95% confi dence interval, 64-74 days), whereas daily treatment with BX471 from week 6 increased mean survival to 86 days (95% confi dence interval, 80-92 days; p = 0.0002). BX471 treatment was associated with less interstitial macrophages, apoptotic tubular epithelial cells, tubular atrophy, interstitial fi brosis, and less globally sclerotic glomeruli as compared to vehicle-treated mice. In contrast, BX471-treated collagen4A3-/-mice showed a higher density of peritubular capillaries. Obviously, blocking CCR1-mediated interstitial macrophage recruitment can maintain peritubular microvasculature and prevent tubular atrophy, two major factors for disease progression in infl ammatory and non-infl ammatory types of progressive nephropathies. These data also indicate the crucial role of macrophage infi ltrates for the progression of chronic kidney disease.
Diabetic Nephropathy
Diabetic nephropathy is the most common type of chronic kidney disease progressing to renal failure. Available rodent models of diabetic nephropathy are frequently used to study the early glomerular changes of diabetic nephropathy [46] . However, rodents usually do not develop advanced interstitial lesions as they occur in late stages of human diabetic nephropathy [47] . Recently, Chow et al. [48] reported that db/db mice develop signifi cant interstitial macrophage infi ltrates at 6 months of age. We injected male db/db mice from 5 months of age for 10 days and obtained renal tissue for histopathological analysis. BX471 reduced the number of macrophages in the renal interstitium as compared to vehicle-treated db/db mice [unpubl. observation], supporting the hypothesis that blocking interstitial macrophage recruitment with CCR1 antagonists may be benefi cial also in diabetic nephropathy.
In summary, CCR1 blockade can effectively prevent recruitment of monocytes and lymphocytes into the renal interstitium. BX471 is effective in multiple models of progressive kidney disease in mice even when treatment was started late in the disease process. Thus, interfering with renal leukocyte recruitment by targeting CCR1 may represent a promising strategy to prevent disease progression in chronic nephropathies characterized by interstitial leukocytic cell infi ltrates.
